NPS Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

27.03.12	NPS Pharmaceuticals to Present at Needham Healthcare Conference (Businesswire)
07.03.12	NPS Pharmaceuticals to Present at Barclays Capital Global Healthcare Conference (Businesswire)
29.02.12	NPS Pharmaceuticals Appoints Georges Gemayel, Ph.D., to Board of Directors (Businesswire)
27.02.12	NPS Pharmaceuticals Observes Rare Disease Day 2012 (Businesswire)
21.02.12	NPS Pharmaceuticals to Present at Upcoming Conferences (Businesswire)
15.02.12	NPS Pharmaceuticals Reports 2011 Year-End Financial Results and 2012 Cash Burn Guidance (Businesswire)
08.02.12	NPS Pharmaceuticals to Report 2011 Financial Results (Businesswire)
06.02.12	NPS Pharmaceuticals to Present at Upcoming Conferences (Businesswire)
31.01.12	NPS Pharmaceuticals Announces FDA Acceptance of New Drug Application for GATTEX® (teduglutide) for the Treatment of Adult Short Bowel Syndrome (SBS) (Businesswire)
05.01.12	NPS Pharmaceuticals to Present at J.P. Morgan Healthcare Conference (Businesswire)
01.12.11	NPS Pharmaceuticals Completes Submission of New Drug Application for GATTEX® (teduglutide) in Adult Short Bowel Syndrome (SBS) (Businesswire)
29.11.11	NPS Pharmaceuticals to Present at Deutsche Bank BioFEST Conference (Businesswire)
29.11.11	Schiff Nutrition International, Inc. Appoints Brian T. Swette to Its Board of Directors (Businesswire)
09.11.11	Forestar Group Inc. Names Anna Torma Senior Vice President - Corporate Affairs (Businesswire)
09.11.11	NPS Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference (Businesswire)
09.11.11	Accuride Corporation Declares Dividend of Preferred Stock Purchase Rights (Businesswire)
07.11.11	NPS Pharmaceuticals Announces Positive Top-Line Results from Pivotal Phase 3 REPLACE Study of NPSP558 in Hypoparathyroidism (Businesswire)
18.11.10	Barnes & Noble Launches NOOKbooks en español™, First Spanish Language Digital Bookstore in the U.S. (Businesswire)
16.09.10	Merck's Non-Profit to Advance Science Education Joins President Obama's Educate to Innovate Campaign (Businesswire)
26.10.09	Data Demonstrate That GATTEX™ (Teduglutide) Improves Lean Body Mass, Mineral Composition and Electrolyte Levels in Patients with Parenteral Nutrition Dependent Short Bowel Syndrome (Businesswire)
24.06.09	NPS Pharmaceuticals President and CEO Dr. Francois Nader Recognized By Ernst & Young as 2009 Entrepreneur of the Year Finalist in New Jersey (Businesswire)
03.06.09	New Findings Demonstrate Potential Benefits of GATTEX™ (teduglutide) in Phase 3 Study of Patients with Short Bowel Syndrome (Businesswire)
08.10.08	One Year of GATTEX(TM) Therapy Safely Reduces Parenteral Nutrition Dependence for Patients with Short Bowel Syndrome (Businesswire)
23.09.08	GATTEX(TM) Abstracts to be Presented at ACG Meeting; 52-Week Data from Phase 3 Clinical Trial Scheduled for Plenary Session (Businesswire)
07.08.08	NPS Pharmaceuticals Reports Second Quarter Financial Results (Businesswire)
08.05.08	GATTEX(TM) Abstracts Accepted for Presentation at DDW Conference; Phase 3 Short Bowel Syndrome Results Scheduled for Oral Plenary Session (Businesswire)
07.05.08	NPS Pharmaceuticals Reports First Quarter 2008 Financial Results and Business Update (Businesswire)
29.04.08	NPS Pharmaceuticals to Report First Quarter 2008 Financial Results (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	30.01	1.66 %	K V
Roche Hldg G	270.60	1.39 %	K V
Part Grp Hldg	1’314.50	1.19 %	K V
Givaudan	3’900.00	0.46 %	K V
Lonza Grp	560.00	0.43 %	K V
Sonova Hldg	295.50	-0.67 %	K V
Swiss Re	133.75	-0.78 %	K V
CieFinRichemont	139.70	-0.89 %	K V
Zurich Insur Gr	542.00	-0.95 %	K V
Kuehne+Nagel Int	201.00	-3.09 %	K V

Nachrichten zu NPS Pharmaceuticals Inc.

Aktien Top/Flop

Meistgelesene Nachrichten